Novel Illumina-based next generation sequencing approach with one-round amplification provides early and reliable detection of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia

Warning

This publication doesn't include Faculty of Medicine. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.

Authors

ROMŽOVÁ Marianna SMITALOVÁ Dagmar TOM Nikola JURČEK Tomáš ČULEN Martin ŽÁČKOVÁ Daniela MAYER Jiří RÁČIL Zdeněk

Year of publication 2020
Type Article in Periodical
Magazine / Source British journal of haematology
MU Faculty or unit

Central European Institute of Technology

Citation
Web https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.16382
Doi http://dx.doi.org/10.1111/bjh.16382
Keywords next generation sequencing; illumina; BCR-ABL1; kinase domain mutation; TKI resistance
Description The occurrence of mutations in the BCR-ABL1 kinase domain (KD) can lead to treatment resistance in chronic myeloid leukaemia patients. Nowadays, next-generation sequencing (NGS) is an alternative method for the detection of kinase domain mutations, compared to routinely used Sanger sequencing, providing a higher sensitivity of mutation detection. However, in the protocols established so far multiple rounds of amplification limit reliable mutation detection to approximately 5% variant allele frequency. Here, we present a simplified, one-round amplification NGS protocol for the Illumina platform, which offers a robust early detection of BCR-ABL1 KD mutations with a reliable detection limit of 3% variant allele frequency.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info